Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/12/2021 | $7.00 | Buy | ThinkEquity |
MINNEAPOLIS, MN, US, Nov. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW)), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal second quarter ended September 30, 2024. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call at 5:00 p.m. Eastern time November 14, 2024 to discuss the results (see dial-in information below). Fiscal Q2 2025 Financial Highlights Revenues totaled $201,000, up 62% sequentially and down 3% from the same year ago period, as the company continued to transition in the current fiscal yea
MINNEAPOLIS, MN, US, Nov. 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Thursday, November 14, 2024 after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day. Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo's Investor Relations website at: https://audience.mysequire.com/webinar-view?webinar_id=6fd4ce0f-76b5-4819-9fd7-a8412e31847e A replay of the webcast wi
Company Reieterates Gudience of 50% to 100% Revenue Growth in Fiscal 2025 MINNEAPOLIS, MN, US, Aug. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal first quarter ended June 30, 2024. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call at 5:00 p.m. Eastern time August 14, 2024 to discuss the results (see dial-in information below). Fiscal Q1 2025 Financial Highlights Revenues increased 6% to $124,000, driven by the increasing roll out and adoption of
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G - PetVivo Holdings, Inc. (0001512922) (Subject)
SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)
MINNEAPOLIS, MN, US, Nov. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW)), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal second quarter ended September 30, 2024. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call at 5:00 p.m. Eastern time November 14, 2024 to discuss the results (see dial-in information below). Fiscal Q2 2025 Financial Highlights Revenues totaled $201,000, up 62% sequentially and down 3% from the same year ago period, as the company continued to transition in the current fiscal yea
MINNEAPOLIS, MN, US, Nov. 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, will report financial results on Thursday, November 14, 2024 after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day. Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo's Investor Relations website at: https://audience.mysequire.com/webinar-view?webinar_id=6fd4ce0f-76b5-4819-9fd7-a8412e31847e A replay of the webcast wi
MINNEAPOLIS, MN, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Cindy Gill to the position of field veterinary business development manager for the entire states of Oklahoma and Arkansas and the northern region of Texas. "Cindy's experience and strong record of sales achievement with veterinary clinics brings to our sales team a valuable resource for achieving our business goals," PetVivo CEO, John Lai. "Her experience with other veterinary products and her knowledge of clinic operations enables her to prioritize and better address the veterinarians and cli
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. IZEA Worldwide The Trade: IZEA Worldwide, Inc. (NASDAQ:IZEA) 10% owner GP Cash Management Ltd acquired a total of 7,136 shares an average price of $2.50. To acquire these shares, it cost around $17,840. What’s Happening: On April 1, IZEA Worldwide
Gainers Kineta (NASDAQ:KA) shares increased by 24.3% to $0.67 during Monday's after-market session. The market value of their outstanding shares is at $7.3 million. Moleculin Biotech (NASDAQ:MBRX) stock increased by 10.21% to $5.6. The company's market cap stands at $12.4 million. Cue Health (NASDAQ:HLTH) stock moved upwards by 6.01% to $0.18. The market value of their outstanding shares is at $29.3 million. Nexalin Technology (NASDAQ:NXL) shares moved upwards by 5.57% to $2.46. The company's market cap stands at $18.2 million. Atara Biotherapeutics (NASDAQ:ATRA) stock moved upwards by 5.52% to $0.8. The market value of their outstanding shares is at $95.2 million. PetVivo Hldgs (NASDA
Gainers Longeveron (NASDAQ:LGVN) shares moved upwards by 75.0% to $3.85 during Monday's pre-market session. The market value of their outstanding shares is at $9.6 million. PetVivo Hldgs (NASDAQ:PETV) stock increased by 17.09% to $1.22. The company's market cap stands at $20.4 million. SHL Telemedicine (NASDAQ:SHLT) stock moved upwards by 13.26% to $6.49. The company's market cap stands at $106.3 million. Pluri (NASDAQ:PLUR) stock moved upwards by 12.02% to $6.15. The market value of their outstanding shares is at $32.1 million. Novo Integrated Sciences (NASDAQ:NVOS) shares moved upwards by 11.35% to $0.5. The company's market cap stands at $8.8 million. Ocugen (NASDAQ:OCGN) stock move
10-Q - PetVivo Holdings, Inc. (0001512922) (Filer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
8-K - PetVivo Holdings, Inc. (0001512922) (Filer)
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)
4/A - PetVivo Holdings, Inc. (0001512922) (Issuer)
4/A - PetVivo Holdings, Inc. (0001512922) (Issuer)
MINNEAPOLIS, MN, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Cindy Gill to the position of field veterinary business development manager for the entire states of Oklahoma and Arkansas and the northern region of Texas. "Cindy's experience and strong record of sales achievement with veterinary clinics brings to our sales team a valuable resource for achieving our business goals," PetVivo CEO, John Lai. "Her experience with other veterinary products and her knowledge of clinic operations enables her to prioritize and better address the veterinarians and cli
MINNEAPOLIS, MN, Sept. 16, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Skylor Walker to the new position of field veterinary business development manager for the entire state of Louisiana and the southern region of Texas. "Skylor's experience and strong record of sales achievement with veterinary clinics brings to our sales team a valuable resource for achieving our business goals," PetVivo CEO, John Lai. "Her experience with other hydrogel injectable products enables us to prioritize and better address the veterinarians and clinics in our sales pipeline."
Expert Capablites of Senior Vet-Tech to Help Drive Greater Adoption of Spryng as Breakthrough Treatment of Osteoarthritis for Companiaon Animals MINNEAPOLIS, MN, & Annapolis Junction, MD, US, Sept. 09, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading biomedical company delivering innovative therapeutic devices for equines and companion animals, has appointed board certified veterinary surgeon, Dr. Kirsty Husby, DVM, MS, DACVS (LA), to the position of senior technical services veterinarian. Dr. Husby brings to PetVivo more than a decade of experience and accomplishment in animal health. This has involved clinical practice and research experience at
ThinkEquity initiated coverage of PetVivo Holdings with a rating of Buy and set a new price target of $7.00
4 - PetVivo Holdings, Inc. (0001512922) (Issuer)